In a significant advance for cancer research, the Mount Sinai Tisch Cancer Center has implemented a new technology that drastically reduces the time required for clinical trial data entry. By integrating electronic health records (EHRs) with clinical trial data collection systems, researchers can now devote more time to critical study components rather than administrative tasks. This innovation not only streamlines the research process but also holds the potential to accelerate the development of new cancer treatments, thereby benefiting patients and caregivers alike.

Efficiency Gains Through EHR-to-EDC Integration

The new system, powered by IgniteData’s Archer platform and integrated with Epic, has demonstrated impressive results in its early implementation phase. Since its launch in 2025, the technology has been adopted across all 16 disease groups at the Mount Sinai Tisch Cancer Center. By automating the transfer of structured clinical information from EHRs into electronic data capture (EDC) systems, the time required for data entry has been reduced from an average of 5.5 minutes to just 2.5 minutes per patient visit—a remarkable decrease of more than 50%. This efficiency not only saves time but also enhances the accuracy of the data collected. Initial evaluations indicate that approximately 70% of the required data on electronic case report forms is now populated automatically during patient visits, with a perfect accuracy rate and no re-query instances. This improvement is crucial, as traditional methods often involve manual data entry, which is prone to errors and can delay the research process.

Impact on Clinical Research and Patient Care

The implications of this technology for clinical trials are profound. Clinical trials play a vital role in determining the safety and effectiveness of new cancer treatments. By expediting the data collection process, researchers can more quickly analyze results, leading to faster conclusions about new therapies. For cancer patients, this could mean quicker access to innovative treatments that have been rigorously evaluated. Moreover, the increased accuracy of data collection enhances the reliability of research findings. Accurate data ensures that the results of clinical trials can be trusted, which is essential for the development of new therapies. Patients can feel more confident that the information being used in trials directly reflects their health, ultimately improving safety and outcomes.

The Role of AI in Cancer Research

The integration of technologies like IgniteData’s Archer platform marks a pivotal moment in the intersection of artificial intelligence and oncology. By automating labor-intensive tasks such as data entry, AI is not only improving operational efficiencies but also allowing researchers to focus on higher-level analysis and patient interactions. This shift towards leveraging technology in clinical trials is a key aspect of precision oncology, where tailored treatments are developed based on individual patient data. As AI continues to evolve, its applications in cancer research will likely expand, offering even more sophisticated tools for data analysis and patient management. This technology is a promising step toward a future where AI plays an integral role in accelerating cancer treatment innovations and improving patient outcomes.

Future Directions for Mount Sinai Tisch Cancer Center

Looking ahead, Mount Sinai Tisch Cancer Center plans to expand its EHR-to-EDC integration to support more complex clinical trial data, including real-world medical histories and laboratory findings. This expansion reflects the center's commitment to enhancing research infrastructure and improving data quality. Additionally, the program will extend to include advanced therapies, such as CAR-T cell therapy, which has shown promise in treating certain types of cancer. The adoption of this technology not only aligns with Mount Sinai's designation as a National Cancer Institute-designated Comprehensive Cancer Center but also underscores its ongoing dedication to advancing cancer research and patient care. With the construction of a new state-of-the-art cancer hospital underway, the center is poised to further enhance its capacity to deliver innovative, patient-centered care.

Conclusion

The recent advancements at the Mount Sinai Tisch Cancer Center exemplify the potential of technology to transform the landscape of cancer research. By reducing data entry time and increasing accuracy, this new EHR-to-EDC integration system is set to improve the efficiency of clinical trials, ultimately bringing new treatments to patients more swiftly. As the field of oncology continues to integrate innovative technologies, the future looks promising for cancer patients and researchers alike. For those interested in staying informed about the latest developments in AI and cancer research, resources like CureCancerWithAi.com provide valuable insights into ongoing advancements and breakthroughs in this rapidly evolving field.

Readers who want more plain-language context on AI and oncology can also explore the Cure Cancer With AI blog and learn more about the project.